[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0619255B8 - composto de peptídeo, composição farmacêutica, uso do composto e medicamento para imunoterapia de câncer - Google Patents

composto de peptídeo, composição farmacêutica, uso do composto e medicamento para imunoterapia de câncer

Info

Publication number
BRPI0619255B8
BRPI0619255B8 BRPI0619255A BRPI0619255A BRPI0619255B8 BR PI0619255 B8 BRPI0619255 B8 BR PI0619255B8 BR PI0619255 A BRPI0619255 A BR PI0619255A BR PI0619255 A BRPI0619255 A BR PI0619255A BR PI0619255 B8 BRPI0619255 B8 BR PI0619255B8
Authority
BR
Brazil
Prior art keywords
compound
cancer immunotherapy
drug
pharmaceutical composition
hydrogen atom
Prior art date
Application number
BRPI0619255A
Other languages
English (en)
Inventor
Gotoh Masashi
Nishihara Toshio
Original Assignee
Chugai Seiyaku Kabishiki Kaisha
Dainippon Sumitomo Pharma Co
Int Inst Cancer Immunology Inc
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Seiyaku Kabishiki Kaisha, Dainippon Sumitomo Pharma Co, Int Inst Cancer Immunology Inc, Sumitomo Dainippon Pharma Co Ltd filed Critical Chugai Seiyaku Kabishiki Kaisha
Publication of BRPI0619255A2 publication Critical patent/BRPI0619255A2/pt
Publication of BRPI0619255A8 publication Critical patent/BRPI0619255A8/pt
Publication of BRPI0619255B1 publication Critical patent/BRPI0619255B1/pt
Publication of BRPI0619255B8 publication Critical patent/BRPI0619255B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

composto de peptídeo, composição farmacêutica, anticorpo, uso do composto e medicamento para imunoterapia de câncer. a presente invenção refere-se a um composto da fórmula (1) em que x é um resíduo de tirosina ou um resíduo de metionina; y e z são, cada, uma ligação simples ou similar; r1 é um átomo de hidrogênio ou similar; r2 é um grupo hidróxi ou similar; r3 é um átomo de hidrogênio, grupo alquila, grupo amino ou similar; r4 é um átomo de hidrogênio, grupo alquila, grupo carbóxi ou similar; m é 1 ou 2; e n é um número inteiro de 0 a 2, com a condição de que quando n é 0, r3 é um átomo de hidrogênio ou um grupo alquila, ou um sal farmaceuticamente aceitável do mesmo, e seu uso em imunoterapia de câncer.
BRPI0619255A 2005-11-30 2006-11-29 composto de peptídeo, composição farmacêutica, uso do composto e medicamento para imunoterapia de câncer BRPI0619255B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005346577 2005-11-30
JP2005-346577 2005-11-30
PCT/JP2006/323827 WO2007063903A1 (ja) 2005-11-30 2006-11-29 新規ペプチド化合物

Publications (4)

Publication Number Publication Date
BRPI0619255A2 BRPI0619255A2 (pt) 2011-09-27
BRPI0619255A8 BRPI0619255A8 (pt) 2015-12-15
BRPI0619255B1 BRPI0619255B1 (pt) 2021-05-11
BRPI0619255B8 true BRPI0619255B8 (pt) 2021-05-25

Family

ID=38092236

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0619255A BRPI0619255B8 (pt) 2005-11-30 2006-11-29 composto de peptídeo, composição farmacêutica, uso do composto e medicamento para imunoterapia de câncer

Country Status (18)

Country Link
US (4) US7939627B2 (pt)
EP (1) EP1961761B1 (pt)
JP (4) JP4394724B2 (pt)
KR (1) KR101385805B1 (pt)
CN (2) CN105315347A (pt)
AU (1) AU2006319892B2 (pt)
BR (1) BRPI0619255B8 (pt)
CA (1) CA2631292C (pt)
DE (1) DE602006017880D1 (pt)
DK (1) DK1961761T3 (pt)
ES (1) ES2352855T3 (pt)
HK (2) HK1122819A1 (pt)
PL (1) PL1961761T3 (pt)
PT (1) PT1961761E (pt)
RU (1) RU2424247C2 (pt)
SI (1) SI1961761T1 (pt)
TW (1) TWI372152B (pt)
WO (1) WO2007063903A1 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE540111T1 (de) 2003-11-05 2012-01-15 Int Inst Cancer Immunology Inc Hla-dr-bindendes antigenpeptid, das von wt1 abgeleitet ist
US8765687B2 (en) 2005-10-17 2014-07-01 Sloan Kettering Institute For Cancer Research WT1 HLA class II-binding peptides and compositions and methods comprising same
BRPI0619255B8 (pt) 2005-11-30 2021-05-25 Chugai Seiyaku Kabishiki Kaisha composto de peptídeo, composição farmacêutica, uso do composto e medicamento para imunoterapia de câncer
ES2591029T3 (es) 2006-04-10 2016-11-24 Sloan Kettering Institute For Cancer Research Péptidos WT-1 inmunogénicos y métodos para su uso
US10139395B2 (en) 2007-02-27 2018-11-27 International Institute Of Cancer Immunology, Inc. Method for activation of helper T cell and composition for use in the method
JP2011016751A (ja) * 2009-07-08 2011-01-27 Sumitomo Chemical Co Ltd 光学活性３−アミノピペリジン−１−カルボキシレート化合物の製造方法およびその製造方法に用いられる中間体
BR112012025047A2 (pt) 2010-03-31 2016-06-21 Stabilitech Ltd formulações líquidas estabilizadas
WO2011121306A1 (en) 2010-03-31 2011-10-06 Stabilitech Ltd. Stabilisation of viral particles
ES2708989T3 (es) 2010-03-31 2019-04-12 Stabilitech Biopharma Ltd Método de conservación de adyuvantes de alumbre y vacunas potenciadas con alumbre
MY170306A (en) 2010-10-05 2019-07-17 Int Inst Cancer Immunology Inc Method for activating helper t cell
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
US9539299B2 (en) * 2011-10-27 2017-01-10 International Institute Of Cancer Immunology, Inc. Combination therapy with WT1 peptide vaccine and temozolomide
US20150104413A1 (en) 2012-01-13 2015-04-16 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
JP6163486B2 (ja) 2012-07-02 2017-07-12 大日本住友製薬株式会社 癌抗原ペプチド経皮剤
BR112015013737B1 (pt) * 2012-12-13 2021-07-27 Ruprecht-Karls-Universitãt Heidelberg Peptídeos com alteração do quadro de leitura msiespecífico (fsp) para a prevenção e tratamento do câncer
MY175935A (en) 2012-12-17 2020-07-15 Int Inst Cancer Immunology Inc Method for activating helper t cell
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
EP3769782A1 (en) * 2013-01-15 2021-01-27 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
CN103961699B (zh) 2013-02-05 2018-11-06 日东电工株式会社 经皮给予用wt1肽癌症疫苗组合物
CA2841014A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Tape preparation of wt1 peptide cancer vaccine for transdermal administration
CN103961702B (zh) 2013-02-05 2019-04-09 日东电工株式会社 粘膜给予用wt1肽癌症疫苗组合物
CN103961307B (zh) 2013-02-05 2019-11-29 日东电工株式会社 经皮给予用wt1肽癌症疫苗组合物
EP2966092A4 (en) * 2013-03-08 2016-11-16 Taiho Pharmaceutical Co Ltd NEW PEPTIDE CARRYING 5 RELATED CTL EPITOPES
US9663563B2 (en) 2013-03-12 2017-05-30 Sumitomo Dainippon Pharma Co., Ltd. Aqueous liquid composition
US10588952B2 (en) 2013-03-29 2020-03-17 Sumitomo Dainippon Pharma Co., Ltd. Conjugate vaccine using trimming function of ERAP1
RU2668560C2 (ru) * 2013-03-29 2018-10-02 Сумитомо Дайниппон Фарма Ко., Лтд. Конъюгированная вакцина на основе пептида антигена wt1
TWI651094B (zh) 2013-10-21 2019-02-21 日商大鵬藥品工業股份有限公司 新穎ｃｔｌ抗原決定部位４連結肽
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
WO2016047797A1 (ja) 2014-09-27 2016-03-31 大日本住友製薬株式会社 注射用医薬組成物
JP6671141B2 (ja) * 2014-10-21 2020-03-25 大日本住友製薬株式会社 懸濁液剤
JP6699013B2 (ja) * 2014-12-25 2020-05-27 国立大学法人三重大学 Ｗｔ１由来ペプチド認識抗体
JP7209963B2 (ja) * 2016-11-30 2023-01-23 住友ファーマ株式会社 Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
JPWO2018181648A1 (ja) 2017-03-30 2020-02-13 大日本住友製薬株式会社 Ｗｔ１癌抗原ペプチドおよびこれを含むペプチドコンジュゲート体
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
EP3858377A4 (en) 2018-09-28 2022-11-30 Sumitomo Pharma Co., Ltd. INJECTABLE COMPOSITION
TWI851607B (zh) 2018-10-05 2024-08-11 日商癌免疫研究所股份有限公司 良性腫瘤之預防或治療藥
WO2020166600A1 (ja) * 2019-02-13 2020-08-20 大日本住友製薬株式会社 システイン残基を有するヘミアスタリン誘導体
MX2021012201A (es) 2019-04-05 2022-01-06 Sumitomo Pharma Co Ltd Adyuvante soluble en agua.
AU2020255935A1 (en) 2019-04-05 2021-12-02 Sumitomo Pharma Co., Ltd. Water soluble adjuvant and composition containing same
EP4151227A1 (en) 2020-05-12 2023-03-22 Sumitomo Pharma Co., Ltd. Pharmaceutical composition for treating cancer
TW202315645A (zh) 2021-08-12 2023-04-16 日商癌免疫研究所股份有限公司 用以處置或預防癌症之醫藥組合物及方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858358A (en) * 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6297041B1 (en) * 1992-03-11 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US6309642B1 (en) * 1997-04-28 2001-10-30 The Research And Development Institute, Inc. Peptides which mimic candida carbohydrate epitopes and their use in a vaccine
US5858682A (en) * 1996-08-02 1999-01-12 Pharmingen E2A/pbx1 fusion protein specific monoclonal antibodies
PT1103564E (pt) * 1998-07-31 2009-03-13 Int Inst Cancer Immunology Inc Antigénios de cancro com base no produto do gene supressor de tumor wt1
TR200101482T2 (tr) 1998-09-30 2002-01-21 Corixa Corporation WT1'e özgü imünoterapi için bileşimler
GB9823897D0 (en) 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
US7534605B2 (en) * 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
KR100863853B1 (ko) 2001-03-22 2008-10-15 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 더블유티1 개변 펩티드
AU2002252638A1 (en) * 2001-04-17 2002-10-28 Children's Hospital Oakland Research Institute Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies
JP5230891B2 (ja) 2001-09-28 2013-07-10 株式会社癌免疫研究所 抗原特異的ｔ細胞の新規な誘導方法
JPWO2003028758A1 (ja) * 2001-09-28 2005-01-13 治夫 杉山 抗原特異的ｔ細胞の誘導方法
US7420034B2 (en) * 2002-06-12 2008-09-02 Dainippon Sumitomo Pharma Co., Ltd. HLA-A24-restricted cancer antigen peptides
AU2003262094A1 (en) * 2002-09-12 2004-04-30 Haruo Sugiyama Cancer antigen peptide preparation
AU2003264514A1 (en) 2002-09-20 2004-04-08 Chugai Seiyaku Kabushiki Kaisha Wt1 substitution peptides
WO2004063924A2 (en) * 2003-01-13 2004-07-29 Sierra Wireless, Inc. Host extensible wireless application interface
US20060217297A1 (en) 2003-01-15 2006-09-28 Haruo Sugiyama Dimerized peptide
US10500257B2 (en) * 2003-06-27 2019-12-10 International Institute Of Cancer Immunology, Inc. Method of selecting WT1 vaccine adaptive patient
ATE540111T1 (de) 2003-11-05 2012-01-15 Int Inst Cancer Immunology Inc Hla-dr-bindendes antigenpeptid, das von wt1 abgeleitet ist
CA2552188A1 (en) * 2003-12-31 2005-07-21 University Of Rochester Polypeptides and immunogenic conjugates capable of inducing antibodies against pathogens, and uses thereof
SI1731605T1 (sl) 2004-03-31 2010-07-30 Internat Inst Of Cancer Immunolog Inc Peptidi antigena karcinoma izvedeni iz WT1
WO2005121178A2 (en) * 2004-06-08 2005-12-22 Wisconsin Alumni Research Foundation Immunoaffinity chromatography polyol-responsive monoclonal antibodies
BRPI0619255B8 (pt) * 2005-11-30 2021-05-25 Chugai Seiyaku Kabishiki Kaisha composto de peptídeo, composição farmacêutica, uso do composto e medicamento para imunoterapia de câncer

Also Published As

Publication number Publication date
KR101385805B1 (ko) 2014-04-16
US8575308B2 (en) 2013-11-05
US20110229506A1 (en) 2011-09-22
TW200730540A (en) 2007-08-16
US9273148B2 (en) 2016-03-01
KR20080073356A (ko) 2008-08-08
JP2009286792A (ja) 2009-12-10
BRPI0619255A8 (pt) 2015-12-15
SI1961761T1 (sl) 2010-12-31
DE602006017880D1 (pt) 2010-12-09
JP4394724B2 (ja) 2010-01-06
ES2352855T3 (es) 2011-02-23
CN101336249A (zh) 2008-12-31
AU2006319892B2 (en) 2012-05-10
RU2424247C2 (ru) 2011-07-20
PL1961761T3 (pl) 2011-04-29
EP1961761A1 (en) 2008-08-27
JPWO2007063903A1 (ja) 2009-05-07
JP2012158597A (ja) 2012-08-23
JP5597668B2 (ja) 2014-10-01
BRPI0619255A2 (pt) 2011-09-27
EP1961761B1 (en) 2010-10-27
RU2008126305A (ru) 2010-01-10
US9765114B2 (en) 2017-09-19
EP1961761A4 (en) 2009-01-21
US20100062010A1 (en) 2010-03-11
US20160168197A1 (en) 2016-06-16
US7939627B2 (en) 2011-05-10
HK1122819A1 (en) 2009-05-29
JP5800928B2 (ja) 2015-10-28
CA2631292C (en) 2014-05-06
JP2014080435A (ja) 2014-05-08
BRPI0619255B1 (pt) 2021-05-11
PT1961761E (pt) 2010-12-16
WO2007063903A1 (ja) 2007-06-07
AU2006319892A1 (en) 2007-06-07
CA2631292A1 (en) 2007-06-07
HK1221230A1 (zh) 2017-05-26
JP5049323B2 (ja) 2012-10-17
TWI372152B (en) 2012-09-11
US20140046036A1 (en) 2014-02-13
DK1961761T3 (da) 2010-11-29
CN105315347A (zh) 2016-02-10

Similar Documents

Publication Publication Date Title
BRPI0619255B8 (pt) composto de peptídeo, composição farmacêutica, uso do composto e medicamento para imunoterapia de câncer
BR112018068278A2 (pt) derivado de 3-desóxi e suas composições farmacêuticas
BR0314113A (pt) Derivados de amino propanol
BRPI0417947A (pt) composto, composição farmacêutica, fabricação de um medicamento para o uso no tratamento e/ou prevenção de um metabólico distúrbio, e, formulação farmacêutica
ECSP067110A (es) Derivados de 2-carbamida-4-feniltiazol, su preparación y su aplicación en terapéutica
MY169272A (en) Her2 antibody composition
BRPI0813244B8 (pt) compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário
BRPI0714885B8 (pt) compostos terapêuticos e seu uso
BRPI0817096B8 (pt) análogo de tiazolidinodiona e composição farmacêutica que o compreende
BRPI0614524B8 (pt) uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, e o referido composto
AR077849A2 (es) Compuestos y composiciones como inhibidores de proteina quinasa
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
BR0311693A (pt) Sal de formato de o-desmetil-venlafaxina
PE20090216A1 (es) Compuestos triazolil aminopirimidina
GEP20104882B (en) Age inhibitors
BRPI0507903A (pt) derivados de quinazolina e composição farmacêutica compreendendo os mesmos
BR0300709A (pt) Sal de perindopril e as composições farmacêuticas contendo o mesmo
BRPI0620985B1 (pt) composição farmacêutica, e usos de derivados de triazina e sensibilizadores de insulina
BRPI0708278B8 (pt) forma cristalina "a" do sal de arginina de perindopril, seu uso, processo para sua preparação e composição farmacêutica
BRPI0418474A (pt) solução aquosa parenteral estável
BR0212353A (pt) Composto, composição farmacêutica, e, uso de um composto
BR0314352A (pt) Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6
UY30356A1 (es) Derivados de 3-halo-n-(2.(4-fluorofenil)-4-oxobutil)-n-metil-5-(trifluorometil)benzamida y composiciones de los mismos.
BR112012009311A2 (pt) composto, composição farmacêutica, e, uso do composto
BR112012009861A2 (pt) composto, composição farmacêutica, e, uso do composto.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.

B25A Requested transfer of rights approved

Owner name: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) , SUMITOMO DAINIPPON PHARMA CO., LTD. (JP)

Owner name: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07K 7/06 (2006.01), A61K 39/00 (2006.01), C07K 14

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/11/2006, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/11/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25D Requested change of name of applicant approved

Owner name: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) ; SUMITOMO PHARMA CO., LTD. (JP)

B25G Requested change of headquarter approved

Owner name: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) ; SUMITOMO PHARMA CO., LTD. (JP)